menu
    • menu
    [{"orgOrder":0,"company":"Bugworks","sponsor":"University Of Tokyo Edge Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"GYROX-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bugworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bugworks \/ University Of Tokyo Edge Capital","highestDevelopmentStatusID":"6","companyTruncated":"Bugworks \/ University Of Tokyo Edge Capital"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"BBV87","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Biotech \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Bharat Biotech \/ CEPI"},{"orgOrder":0,"company":"Bugworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BWC0977","moa":"Bacterial topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bugworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bugworks \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bugworks \/ Inapplicable"},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Vaxart","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Centaur Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Centaur Pharmaceuticals \/ Vaxart","highestDevelopmentStatusID":"6","companyTruncated":"Centaur Pharmaceuticals \/ Vaxart"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tetravalent Dengue Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ChAdOx1 biEBOV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ University of Oxford","highestDevelopmentStatusID":"6","companyTruncated":"Serum Institute of India \/ University of Oxford"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ZY-19489","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gennova Biopharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Gennova Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Gennova Biopharmaceuticals \/ CEPI"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gennova Biopharmaceuticals

                            India arrow
                            IFT FIRST
                            Not Confirmed

                            Gennova Biopharmaceuticals

                            India arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : CEPI

                            Deal Size : $13.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Gennova Expands CEPI Partnership for Nipah Virus saRNA Vaccine Development

                            Details : The funding aims to advance the clinical development of company's early-stage clinical trial studies for the treatment of Nipah virus infection.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 01, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : CEPI

                            Deal Size : $13.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Serum Institute of India

                            India arrow
                            IFT FIRST
                            Not Confirmed

                            Serum Institute of India

                            India arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetravalent Dengue Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CDSCO panel gives nod for continuation of phase-II clinical trial of SII's dengue vaccine

                            Details : Dengusiil is a tetravalent live attenuated dengue vaccine, which is being developed for the treatment of dengue.

                            Product Name : Dengusiil

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 06, 2024

                            Lead Product(s) : Tetravalent Dengue Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Serum Institute of India

                            India arrow
                            IFT FIRST
                            Not Confirmed

                            Serum Institute of India

                            India arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ChAdOx1 biEBOV

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : University of Oxford

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Serum Institute to Produce Ebola Vaccine for Use in Uganda Outbreak

                            Details : ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm. The vaccine will be administered intramuscularly (IM).

                            Product Name : ChAdOx1 biEBOV

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 17, 2022

                            Lead Product(s) : ChAdOx1 biEBOV

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : University of Oxford

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bharat Biotech

                            India arrow
                            IFT FIRST
                            Not Confirmed

                            Bharat Biotech

                            India arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBV154

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NTAGI May Soon Review Efficacy Data of India's First Intranasal Covid Vaccine

                            Details : India's drug controller had in January this year given permission to Bharat Biotech to conduct standalone on its Covid-19 intranasal vaccine. The phase 3 trials of the intranasal vaccine candidate BBV154 (Chad SARS-COV-2) are underway and likely to be co...

                            Product Name : BBV154

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 06, 2022

                            Lead Product(s) : BBV154

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zydus Lifesciences

                            India arrow
                            IFT FIRST
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZY-19489

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zydus Receives Orphan Drug Designation From US FDA for ZY-19489, A Novel Compound to Treat Malaria

                            Details : Orphan drug designation is based on Phase I study of ZY19489, a novel antimalarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug-resistant strains.

                            Product Name : ZY-19489

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 16, 2021

                            Lead Product(s) : ZY-19489

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bugworks

                            India arrow
                            IFT FIRST
                            Not Confirmed

                            Bugworks

                            India arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BWC0977

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bugworks Research Begins First in Human Phase 1 Study of BWC0977 to Treat Critical Bacterial Infections

                            Details : BWC0977 is a highly potent, intravenous broad-spectrum antibiotic with the potential for oral administration, for the treatment of serious multi drug resistant (MDR) gram-negative infections.

                            Product Name : BWC0977

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 11, 2021

                            Lead Product(s) : BWC0977

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bharat Biotech

                            India arrow
                            IFT FIRST
                            Not Confirmed

                            Bharat Biotech

                            India arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBV154

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : AIIMS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AIIMS Delhi to Conduct Phase 2 of Bharat Biotech's Nasal Vaccine Trials

                            Details : Bharat Biotech's intranasal vaccine, BBV154, received regulatory approval for second phase trials in August. The trials will begin in a couple of weeks after permission is granted by the committee.

                            Product Name : BBV154

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 09, 2021

                            Lead Product(s) : BBV154

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : AIIMS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bharat Biotech

                            India arrow
                            IFT FIRST
                            Not Confirmed

                            Bharat Biotech

                            India arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBV152

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bharat Biotech to Start Phase-1 Trials of Covid-19 Intranasal Vaccine in Feb-March

                            Details : BBV154 (intranasal Covid-19 vaccine), preclinical testing has been completed for toxicology, immunogenicity and challenge studies. The Phase-1 trials will be conducted in Saint Louis University's Vaccine and Treatment Evaluation Unit.

                            Product Name : Covaxin

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 01, 2021

                            Lead Product(s) : BBV152

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Centaur Pharmaceuticals

                            India arrow
                            IFT FIRST
                            Not Confirmed

                            Centaur Pharmaceuticals

                            India arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXA-CoV2-1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Vaxart

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            KindredBio Expands Manufacturing Agreement with Vaxart

                            Details : The manufacturing services will be performed via Centaur Biopharmaceutical Services (Centaur), a wholly owned subsidiary of KindredBio that provides full service contract development and manufacturing services.

                            Product Name : VXA-CoV2-1

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 10, 2020

                            Lead Product(s) : VXA-CoV2-1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Vaxart

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Bugworks

                            India arrow
                            IFT FIRST
                            Not Confirmed

                            Bugworks

                            India arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GYROX-1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : University Of Tokyo Edge Capital

                            Deal Size : $7.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Bugworks Raises US$7.5M From a Global Investment Syndicate to Combat the Global Challenge Posed by Deadly Bact...

                            Details : This investment enables Bugworks to complete Phase 1 studies for its GYROX series Intravenous drug candidate and advance an Oral lead towards clinical development.

                            Product Name : GYROX-1

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 22, 2020

                            Lead Product(s) : GYROX-1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : University Of Tokyo Edge Capital

                            Deal Size : $7.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth